The digital endpoint solution your pharma clients need
When your pharmaceutical or gene therapy clients ask about digital endpoints for CNS trials, NeuroQuantix gives you a validated, published, regulation-ready answer — backed by data you can reference directly in your advisory.
Strengthen your advisory with data-backed recommendations
Your clients rely on your expertise to select the right tools for their clinical programs. When you recommend NeuroQuantix, you are recommending a platform grounded in 300+ peer-reviewed studies with a published scoping review in Movement Disorders Clinical Practice.
We provide consultants with briefing packages, technical summaries, and effect size comparisons that you can incorporate directly into your client presentations and regulatory strategy documents.
Published Evidence Base
Scoping review of 120 studies (1,407 citations screened). Every claim backed by published data with DOI references.
Effect Size Comparisons
Head-to-head quantified advantages over UPDRS, TETRAS, and other traditional scales. Ready for your client presentations.
Regulatory Pathway Clarity
COA/DDT qualification pathway and 510(k) predicate device analysis. Clear regulatory strategy your clients can evaluate.
Sample Size Advantage
Published data showing ~3x fewer subjects per arm. Translate that directly into timeline and cost savings for your client.
Data points for your presentations
Key metrics and published findings you can reference directly in client-facing materials.
Tremor velocity spectral peak test-retest reliability
Haubenberger et al. 2011
PD detection via CISP composite (speed × pressure)
Zham et al. 2017
PD vs. HC discrimination on absolute acceleration
Published literature
PD detection via pen tilt-pressure analysis
Published literature
Subjects needed for 50% reduction detection at 95% power (ET)
Haubenberger et al. 2011
CISP correlation with UPDRS motor severity
Zham et al. 2017
How we work with consultants
Briefing Package
We provide a comprehensive technical brief covering the platform, evidence base, regulatory pathway, and effect size data — formatted for client presentation.
Client Introduction
When your client is ready, we engage directly with their clinical team to scope integration, discuss trial-specific endpoints, and provide a detailed technical proposal.
Ongoing Collaboration
We support your advisory role with updated data, regulatory developments, and endpoint strategy input throughout the client engagement.
Request a consultant briefing
Get the technical brief, effect size comparisons, and regulatory pathway documentation you need to recommend NeuroQuantix to your clients with confidence.
Request Briefing Package